A Phase III double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Drug A in patients with moderate to severe chronic back pain.
About PRA Health Sciences
We are a global healthcare intelligence partner, consistently ranked among the top CROs and best employers worldwide.
Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.